Abstract

Human stem cells have become one of the hottest areas in biotechnology as several companies have jumped in to try to exploit them commercially in medical therapies. Geron Corp. nabbed the early lead in exploiting embryonic and primordial fetal stem cells through its funding of their isolation; most of the other companies are working with adult stem cells, which pose fewer ethical problems because they can be obtained from sources other than embryos or aborted fetuses. Some of these companies are already moving their stem cell products into clinical trials, to use, for example, in restoring cancer patients' immune systems after intense radiation or chemotherapy. But no one yet knows which companies--if any--will win their high-stakes gamble on stem cells.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.